Assessment of insulin-like growth factors and mutagen sensitivity as predictors of lung cancer risk.
Wu
Xifeng
X
Department of Epidemiology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Yu
He
H
Makan
Nimisha
N
Spitz
Margaret R
MR
D015123:7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide / Q000494:pharmacology; D001761:Bleomycin / Q000494:pharmacology; D002842:Chromatids / Q000473:pathology; D002869:Chromosome Aberrations; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D007335:Insulin-Like Growth Factor II / Q000032:analysis*; D008175:Lung Neoplasms / Q000097:blood* / Q000175:diagnosis; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D009152:Mutagenicity Tests; D009153:Mutagens / Q000494:pharmacology*; D011237:Predictive Value of Tests; D012307:Risk Factors
D018972:Insulin-Like Growth Factor Binding Protein 3; D009153:Mutagens; D001761:Bleomycin; D015123:7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II